Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: venomics - QRxPharma

Drug Profile

Research programme: venomics - QRxPharma

Alternative Names: Haempatch; Q 70050; Q 8008; Q 8009; Q 8010; Textilinin

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator QRxPharma
  • Developer QRxPharma; The University of Queensland
  • Class Enzymes; Peptides; Venoms
  • Mechanism of Action Plasmin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Haemorrhage

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Haemorrhage in Australia (Parenteral)
  • 31 Dec 2008 Early research is ongoing in Australia
  • 03 Feb 2005 Early research in Haemorrhage in Australia (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top